Search

Displaying results 1511 - 1520 of 2435 in total
  1. Drug

    Cinchonidine

    go.drugbank.com/drugs/DB16831
    Experimental

    Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  2. Drug

    Tyrosol

    go.drugbank.com/drugs/DB16855
    Experimental

    Synonyms: p-TyrosolCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 Substrates
  3. Drug

    Norclobazam

    go.drugbank.com/drugs/DB17092
    Investigational

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Substrates
  4. Drug

    Redaporfin

    go.drugbank.com/drugs/DB17219
    Investigational

    Categories: P-glycoprotein substrates
  5. Drug

    P-BCMA-101

    go.drugbank.com/drugs/DB17371
    Investigational

    P-BCMA-101 is an autologous CAR-T therapy developed using Poseida’s piggyBac platform technology.

  6. Drug

    Linafexor

    go.drugbank.com/drugs/DB18031
    Investigational

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  7. Drug

    Gunagratinib

    go.drugbank.com/drugs/DB18191
    Experimental

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  8. Drug

    Nerandomilast

    go.drugbank.com/drugs/DB18237
    ApprovedInvestigational

    Nerandomilast is a phosphodiesterase 4 (PDE4) inhibitor that preferentially inhibits the PDE4B subtype. It has one chiral center and is the R-stereoisomer. On October 7, 2025, nerandomilast was approved as the first new treatment for idi...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  9. Drug

    Elzasonan

    go.drugbank.com/drugs/DB18969
    Investigational

    Elzasonan is under investigation in clinical trial NCT00275197 (A Research Study to Compare the Treatments of a Combination of Elzasonan With Zoloft, to Zoloft Alone, or Placebo in People With Major Depressive Disorder (MDD)).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Substrates
  10. Drug

    Sevasemten

    go.drugbank.com/drugs/DB18983
    Investigational

    Sevasemten is under investigation in clinical trial NCT05291091 (Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates